Key facts
- Notable investors include Charles River Incubator Program, Children's Tumor Foundation, Deep Science Ventures, Nothing is Forever.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for CureAge Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for CureAge Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CureAge Therapeutics
Developer of genetic therapies designed to treat peripheral nerve disorders. The company specializes in ribonucleic acid systems with a focus on neurofibromatosis and gene therapy platforms tailored for rare neurological conditions, enabling patients with inherited nerve disorders to access targeted and potentially transformative treatments.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 5
- Website
- cureagetx.com/
- Ownership
- Privately Held (backing)
CureAge Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CureAge Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CureAge Therapeutics in its N-PORT filings yet. We sweep new filings monthly.